Table 3 AST profile per bacteria (Enterobacterales)
Enterobacterales | Whole-group | Escherichia coli | Klebsiella pneumoniae/sp. | Enterobacter cloacae/sp. | Serratia marcescens | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
COVID + (n; %) | COVID-(n; %) | p-value | COVID + (n; %) | COVID-(n; %) | p-value | COVID + (n; %) | COVID-(n; %) | p-value | COVID + (n; %) | COVID-(n; %) | p-value | COVID + (n; %) | COVID-(n; %) | p-value | |
β-lactam (n; % of evaluated in the respective group) | –* | –* | –* | – | – | < 0.05 | < 0.05 < 0.05 | – | – | – | – | ||||
WT | –* | –* | –* | 27 (39.1) | 6 (42.9) | – | 29 (22.3)/49 (37.7) | 9 (90.0)/12 (57.1) | < 0.05/–a | 24 (47.1)/25 (46.3) | 4 (40)/6 (50) | –/– | – | – | |
Cephalosporinase | –* | –* | –* | 6 (8.7) | 4 (28.6) | < 0.05 | 3 (2.3)/34 (26.2) | 0 (0)/4 (19) | –/– | – | – | – | 31 (93.9) | 8 (88.9) | – |
HC | –* | –* | –* | 3 (4.3) | 0 (0) | – | 4 (3.1)/25 (19.2) | 1 (10.0)/5 (23.8) | –/– | 14 (27.4)/14 (25.9) | 6 (60)/6 (50) | < 0.05/– | 2 (6.1) | 1 (11.1) | – |
e-ESBL | –* | –* | –* | 15 (21.7) | 1 (7.1) | – | 18 (13.8)/19 (14.6) | 0 (0)/0 (0) | –/–a | 9 (17.6)/9 (16.7) | 0 (0)/0 (0) | –/– | – | – | – |
HP | –* | –* | –* | 18 (26.1) | 3 (21.4) | – | – | – | – | – | – | –/– | – | – | – |
CPE | –* | –* | –* | – | – | – | 1 (0.8)/3 (2.3) | 0 (0)/0 (0) | –/– | 4 (7.8)/4 (7.4) | 0 (0)/0 (0) | –/– | – | – | – |
Aminoglycosides-resistant (n; % of evaluated in the respective group) | 72 (13.9) | 14 (20.0) | < 0.05 | 8 (11.6) | 2 (14.3) | – | 20 (0)/23 (17.6) | 1 (10.0)/1 (4.8) | –/– | 10 (20.8)/10 (19.6) | 1 (11.1)/1 (9.0) | –/– | 13 (44.8) | 1 (12.5) | < 0.05 |
Quinolone-resistant (n; % of evaluated in the respective group) | 60 (17.8) | 7 (9.7) | – | 18 (26.9) | 2 (14.2) | – | 18 (32.7)/22 (16.8) | 1 (10)/1 (4.8) | –/– | 12 (23.5)/12 (22.6) | 3 (30)/3 (27.3) | –/– | 0 (0) | 0 (0) | – |
Fosfomycin-resistant (n; % of evaluated in the respective group) | 59 (29.8) | 6 (15.0) | –a | 2 (5.7) | 0 (0) | – | 17 (48.6)/40 (47.1) | 2 (40)/3 (25) | –/– | 6 (22.2)/6 (20) | 1 (14.2)/1 (12.5) | –/– | – | – | – |
Cotrimoxazole-resistant (n; % of evaluated in the respective group) | 67 (18.5) | 4 (6.1) | < 0.05 | 19 (28.4) | 0 (0) | – | 21 (39.6)/23 (18.4) | 0 (0)/0 (0) | < 0.05/– | 13 (26.0)/13 (24.5) | 2 (20)/2 (18.2) | –/– | 0 (0) | 0 (0) | – |